Mylan’s ‘Investor Logic’ For Acquisition Could Support Perrigo’s Rejection
This article was originally published in The Tan Sheet
Executive Summary
Mylan targeted Perrigo as soon as it could, after acquiring Abbott Laboratories’ non-U.S. developed markets in June 2014, says CEO Heather Bresch. Her remarks at investor conference could lend support to Perrigo’s argument that Mylan’s offer does not acknowledge the value of its Omega Pharma acquisition.